Search research articles
Contact Us
Filters
Showing results (161-170 of 174) with videos related to
Page
of 18
Sort By:
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
November 14, 1997
Membrane CD22 defines circulating myeloma-related cells as mature or later B cells
V Perfetti, M C Vignarelli, V Bellotti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 1996
Vinblastine, bleomycin, and methotrexate chemotherapy plus extended-field radiotherapy in early, favorably presenting, clinically staged Hodgkin's patients: the Gruppo Italiano per lo Studio dei Linfomi Experience
P G Gobbi, C Pieresca, A Frassoldati, et al.
Haematologica
|
July 18, 2000
Lomustine and melphalan cannot be replaced by cyclophosphamide and etoposide without reducing efficacy in MOPPEBVCAD chemotherapy for advanced Hodgkin's disease
P G Gobbi, C Broglia, R Bertè, et al.
Blood
|
May 16, 1998
Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease
P G Gobbi, C Pieresca, M L Ghirardelli, et al.
Haematologica
|
April 11, 2000
The role of surgery in the treatment of gastrointestinal lymphomas other than low-grade MALT lymphomas
P G Gobbi, M L Ghirardelli, C Cavalli, et al.
British Journal of Cancer
|
March 1, 1996
Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma
S Brugnatelli, A Riccardi, G Ucci, et al.
International Journal of Oncology
|
May 12, 2011
A prospective, controlled, nonrandomized study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple-myeloma
A Riccardi, G Ucci, S Brugnatelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2001
Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance
P G Gobbi, M L Ghirardelli, M Solcia, et al.
Tumori
|
December 23, 1998
Myeloprotective effect of early primary granulocyte-colony stimulating factor during six courses of intensified 5-fluorouracil, epirubicin and cyclophosphamide (120FEC) chemotherapy for advanced breast cancer. Cooperative Group of Study and Treatment of Breast Cancer
A Riccardi, S Brugnatelli, M Giordano, et al.
International Journal of Clinical & Laboratory Research
|
August 5, 1998
The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy
F Dammacco, F Silvestris, G L Castoldi, et al.
Page
of 18
Search research articles
Search
Showing results (161-170 of 174) with videos related to
Sort By:
Page
of 18
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
November 14, 1997
Membrane CD22 defines circulating myeloma-related cells as mature or later B cells
V Perfetti, M C Vignarelli, V Bellotti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 1996
Vinblastine, bleomycin, and methotrexate chemotherapy plus extended-field radiotherapy in early, favorably presenting, clinically staged Hodgkin's patients: the Gruppo Italiano per lo Studio dei Linfomi Experience
P G Gobbi, C Pieresca, A Frassoldati, et al.
Haematologica
|
July 18, 2000
Lomustine and melphalan cannot be replaced by cyclophosphamide and etoposide without reducing efficacy in MOPPEBVCAD chemotherapy for advanced Hodgkin's disease
P G Gobbi, C Broglia, R Bertè, et al.
Blood
|
May 16, 1998
Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease
P G Gobbi, C Pieresca, M L Ghirardelli, et al.
Haematologica
|
April 11, 2000
The role of surgery in the treatment of gastrointestinal lymphomas other than low-grade MALT lymphomas
P G Gobbi, M L Ghirardelli, C Cavalli, et al.
British Journal of Cancer
|
March 1, 1996
Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma
S Brugnatelli, A Riccardi, G Ucci, et al.
International Journal of Oncology
|
May 12, 2011
A prospective, controlled, nonrandomized study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple-myeloma
A Riccardi, G Ucci, S Brugnatelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 7, 2001
Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance
P G Gobbi, M L Ghirardelli, M Solcia, et al.
Tumori
|
December 23, 1998
Myeloprotective effect of early primary granulocyte-colony stimulating factor during six courses of intensified 5-fluorouracil, epirubicin and cyclophosphamide (120FEC) chemotherapy for advanced breast cancer. Cooperative Group of Study and Treatment of Breast Cancer
A Riccardi, S Brugnatelli, M Giordano, et al.
International Journal of Clinical & Laboratory Research
|
August 5, 1998
The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy
F Dammacco, F Silvestris, G L Castoldi, et al.
Page
of 18